[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TET2

Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF12851 Oxygenase domain of the 2OGFeDO superfamily
Function

Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0001889 liver development
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002318 myeloid progenitor cell differentiation
GO:0006206 pyrimidine nucleobase metabolic process
GO:0006211 5-methylcytosine catabolic process
GO:0006304 DNA modification
GO:0006479 protein methylation
GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0008213 protein alkylation
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009112 nucleobase metabolic process
GO:0009791 post-embryonic development
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018023 peptidyl-lysine trimethylation
GO:0018205 peptidyl-lysine modification
GO:0019857 5-methylcytosine metabolic process
GO:0019858 cytosine metabolic process
GO:0020027 hemoglobin metabolic process
GO:0022612 gland morphogenesis
GO:0030099 myeloid cell differentiation
GO:0032259 methylation
GO:0034968 histone lysine methylation
GO:0035510 DNA dealkylation
GO:0043413 macromolecule glycosylation
GO:0043414 macromolecule methylation
GO:0044270 cellular nitrogen compound catabolic process
GO:0044728 DNA methylation or demethylation
GO:0046700 heterocycle catabolic process
GO:0048536 spleen development
GO:0048732 gland development
GO:0048872 homeostasis of number of cells
GO:0051568 histone H3-K4 methylation
GO:0061008 hepaticobiliary system development
GO:0061484 hematopoietic stem cell homeostasis
GO:0070085 glycosylation
GO:0070988 demethylation
GO:0070989 oxidative demethylation
GO:0072001 renal system development
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072529 pyrimidine-containing compound catabolic process
GO:0072576 liver morphogenesis
GO:0080111 DNA demethylation
GO:0080182 histone H3-K4 trimethylation
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0005506 iron ion binding
GO:0008198 ferrous iron binding
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016706 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors
GO:0051213 dioxygenase activity
GO:0070579 methylcytosine dioxygenase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-5221030: TET1,2,3 and TDG demethylate DNA
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TET2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TET2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29849141Chronic Lymphocytic LeukemiaResistant to immunotherapyTET2-disrupted CAR T cells exhibited an epigenetic profile consistent with altered T cell differentiation and, at the peak of expansion, displayed a central memory phenotype. Experimental knockdown of TET2 recapitulated the potency-enhancing effect of TET2 dysfunction in this patient's CAR T cells.
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TET2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TET2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1430.638
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.240.713
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0780.894
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1570.656
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.40.876
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1490.963
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0530.884
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0240.987
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0770.961
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5370.393
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0670.211
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0890.18
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TET2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111318.2018.20.199
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TET2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TET2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TET2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TET2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TET2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TET2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTET2
Nametet methylcytosine dioxygenase 2
Aliases FLJ20032; KIAA1546; tet oncogene family member 2; probable methylcytosine dioxygenase TET2; Methylcytosine d ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TET2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.